1. In Vivo
  2. >>Growth

Deals In 2023: Partnerships And Modest M&A

 
• By Melanie Senior

Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.  

Small growth
• Source: Shutterstock

Dealmaking will continue to pick up in 2023, but don’t expect mega-mergers. That’s the message from many industry-watchers, chastened by a largely forgettable 2022 that failed to deliver the expected dealmaking frenzy as biotech valuations plunged. A more aggressive Federal Trade Commission (FTC), a still-fragile macro-economic environment, plus the uncertain specter of US drug price controls mean buyers are hesitant.

In 2022, total biopharma M&A reached about $80bn – nearly a third of which came from Amgen, Inc.’s proposed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Growth

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

 
• By David Wild

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

More from In Vivo

Pharma’s Dance With Trump Risks Distracting From Longer-Term Threats

 
• By Melanie Senior

Industry is trying to side-step President Trump’s tariff- and price-curbing policy proposals. It may do better facing up to enduring R&D productivity and drug affordability challenges.

Tackling Fraud In The UK: Pharma, Are You Ready?

 
• By Trevor Francis

UK pharma faces a critical turning point as the Economic Crime and Corporate Transparency Act introduces the "Failure to Prevent Fraud" offense in September 2025, requiring companies to transform their approach to fraud prevention or face severe consequences.

Rising Leaders 2025: Kura Oncology’s Mollie Leoni On Setting Precedent, Not Following It

 
• By Jo Shorthouse

Kura Oncology's new chief medical officer discusses her path to leadership, the company's advancing AML pipeline, and her methodical approach to developing treatments for underserved oncology indications.